Quali informazioni dai trial clinici controllati (farmacologici e non), per la terapia antiaritmica nella prevenzione della morte improvvisa?

Giornale Italiano di Cardiologia

Volumn 26, Issue 11, 1996, Pages 1345-1364

  Naccarella, Franco ^a   Croci, Francesco ^b  

^a MAGGIORE HOSPITAL   (Italy)

^b Servizio di Cardiol   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DEFIBRILLATOR; HEART ARRHYTHMIA; MORTALITY; REVIEW; SUDDEN DEATH;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CONTROLLED CLINICAL TRIALS; DEATH, SUDDEN; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE;

EID: 0030280986     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (155)

1. 1A. What's what. A cardiovascular trial guide. ASTRA. 2 edition 1995.
2. 2A. Reiffel JA, Estes III, N.A.M.: A consensus report on antiarrhythmic drug use. Clin Cardiol 1994; 17: 103-116.
3. 3A. Kastritis D, Camm J: Antiarrhythmic drug classification and the clinician: a gambit in the land of chaos. Clin Cardiol 1994; 17: 142-148.
4. 4A. Wyse DG, Hallstrom A, McBride R, CAST Investigators: Events in the cardiac arrhythmia suppression trial (CAST): mortality in patients surviving open lable titration, but not randomized to double blind therapy. J Am Coll Cardiol 1991; 18: 20-28.
5. 5A. Epstein AE, Bigger T: Events in the cardiac arrhythmia suppression trial (CAST): mortality in the entire population. JACC 1991; 18: 14-19.
6. 6A. Anderson JL, Platia EV, Hallstrom A: Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the cardiac arrhythmia suppression trial (CAST). Circulation 1994; 90: 2843-2852.
7. 7A. Peters RW, Mitchell LB, Brooks M: Circadian pattern of arrhythmic death in patients receiving encainide flecainide, or moricizine in the cardiac arrhythmia suppression trial (CAST). J Am Coll Cardiol 1994; 23: 283-289.
8. 8A. Halstrom AL, Greig M, Pratt, Greene L: Relations between heart failure, ejection fraction, arrhythmia suppression and mortality; analysis of the cardiac arrhythmia suppression trial (CAST). J Am Coll Cardiol 1995; 25: 1250-1257.
9. 9A. Merino P, Nidasio G, Franzosi MG: Frequency of predischarge ventricular arrhythmias in Post myocardial infarction patients depends on residual left ventricular pump performance and is independent of the occurrence of acute reperfusion. GISSI 2 Investigators. JACC 1994; 23: 290-295.
10. 10A. Morganroth J, Goin JE: Quinidine-related mortality in the short to medium term treatment of ventricular arrhythmias: a meta analysis, Circulation 1991; 84: 5: 1977-1983.
11. 11A. Herre JM, Titus C et al: Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Ann Intern Med 1190; 113, 671-676.
12. 12A. Anderson JL: Reassessement of benefit-risk ratio and treatment algorithms for antiarrhythmic therapy after the Cardiac Arrhythmia Suppression Trial. J Clin Pharmacol 1990; 30: 981-989.
13. 13A. Abstracts and Final Program of the 14 the Annual Scientific Session of the NASPE, North American Society of Pacing and Electrophysiology. San Diego, California, USA 1993.
14. 14A. Naccarella F, Bracchetti D, Accorsi A et al: L'uso della terapia antiaritmica alla luce dei grandi trial clinici controllati. Informazioni utili anche da trial non controllati? Aggiornamenti in Cardiologia 1995, Atti del X Congresso Meridionale di Cardiologia. Reggio Calabria 3-4 Novembre 1995. E. Adornato Editore.
15. 15A. Minicourse 8: Prevention of cardiac arrest in high risk individuals: data from epidemiologic studies and randomized trials. M.J. Domanski, R.J. Myerburg. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
16. 16A. Clinical tutorials 17: Selecting the best antiarrhythmic drug for sudden death: betablockers, sotalol, amiodarone or pure class IIIs. R.J. Sung., P. Dorian., NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
17. 17A. Chatterjee K, Lazzera R, Clinical trials update Session: New therapeutic strategies emerging from clinical trials. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
18. 1B. Biblo LA, Cerlson MD: Insights into the electrophysiologic study versus electrocardiographic monitoring trial (ESVEM): its programmed stimulation protocol may indroduce bias when assessing long term antiarrhythmic drug therapy. J Am Coll Cardiol 1995; 25: 1601-1604.
19. 2B. Mason JW: An interpretation of the ESVEM study, in M. Santini editore, Progress in Clinical Pacing 1994, Chapter 54, 791-798. Futura Publishing Company Inc Armonk New York 10504, 14995.
20. 3B. Singh BN, Kehoe R, Woosley RL, Scheinman M: Multicenter trial of Sotalol compared with Procainamide in the suppression of inducible ventricular tachycardia: a double blind randomized parallel evaluation. Am Heart J 1995; 129: 87-97.
21. 4B. Mason JW: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 7: 452-458.
22. 5B, Vanoli E, Priori S, Lazzara R, Schwartz PJ: Sympathetic activation, ventricular repolarization and I kr Blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol 1995; 25: 1609-1614.
23. 6B. Sager PT, Nademanee K, Antimisiaris M: Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCL in humans. Circulation 1993; 88: 1072-1082.
24. 7B. Kehoe RF, MacNeil DJ: Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents. Am J Cardiol 1993; 72: 4: 56A-66A.
25. 8B. Katagonis LA, Anderson JL: Electrophysiologic effects of antiarrhythmic drug therapy in the prediction of successful suppression of induced ventricular tachycardia. Am Heart J 1995; 129: 343-349.
26. 9B. Claudel JP, Touboul P: Sotalol: from just another beta-blocker to the prototype of class III antidysrhythmic compound. PACE 1995; 18Pt I: 451-467.
27. 10B. Winters SL, Curwen JH: Sotalol and the management of ventricular arrhythmias: implications of ESVEM. PACE 1995; 18 Pt I, 377-390.
28. 11B. Young GD, Kerr CR: Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. Am J Cardiol 1994; 73: 677-682.
29. 12B. Men KC, Williamson BD: Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 1994; 74: 1119-1123.
30. 13B. Kus T, Campa MA et al: Efficacy and electrophysiological effects of oral sotalol in patients with ventricular tachycardia caused by coronary artery disease. Am Heart J 1992; 123: 82-89.
31. 14B. Naccarella F, Palmieri M, Barbato G, Meda M: After ESVEM trial, can electropharmacological testing still be considered the most usefull strategy to guide therapy in patients with sustained ventricular arrhythmias? In Proceedings of the Controversie in Aritmologia Clinica, Cento Ferrara 1994.
32. 1C. Doval HG, Nul DR: Studio Randomizzato sull'impiego di amiodarone in basse dosi nell'insufficienza cardiaca congestizia grave (GESICA Trial). The Lancet. Ed 1t. 1994; 344: 493-98.
33. 2C. Singh SS, Flecther RD: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. The survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995; 333: 77-82.
34. 3C. Schwartz PJ, Camm J, Janse M, On behalf of the EMIAT investigators: EMIAT: european myocardial infarct amiodarone trial in M. Santini editore, Progress in Clinical Pancing 1994, Chapter 55, 799-807. Futura Publishing Company Inc Armonk New York 10504, 1995.
35. 4C. EMIAT, Abstracts and Final Program of the 16th annual scientific session of the NASPE, North American Society of Pacing and Electrophysiology. Boston, Massachusetts, USA 1995.
36. 5C. EMIAT, SWORD Atti del Cardiac Arrhythmias, fourth international workshop, Venezia 6/8 ottobre 1995.
37. 6C. Greene HL, Poole JE: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (The CASCADE study). Am J Cardiol 1993; 72: 3, 280-287.
38. 7C. Moss AJ for the MADIT investigators: Multicenter Automatic Defibrillator Implantation Trial (MADIT). In Chatterjee K, Lazzara R, Clinical trials update. Session: New therapeutic strategies emerging from clinical trials. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
39. 8C. Kowey PT, Levine JH, Herre JA et al: Randomized, double blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995; 92: 3255-3263.
40. 9C. Calkins H, Sousa J: Reversal of antiarrhythmic drug effects by epinephrine: quinidine versus amiodarone. J Am Coll Cardiol 1992; 19: 347-352.
41. 10C. Olson PJ, Woelfel A: Stratification of sudden death risk in patients receiving long term amiodarone treatment for sustained ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1993; 71: 10, 823-826.
42. 11C. Dimarco JP: Epinephrine infusions during antiarrhythmic drug evaluations: toward a better understanding of drug activity. J Am Coll Cardiol 1992; 19: 2, 353-354.
43. 12C. Loring SJ, Meyers MM, Zaher G, Simonson J: High dose oral amiodarone loading: electrophysiologic effects and clinical tolerance. J Am Coll Cardiol 1992; 19: 169-173.
44. 13C. Teo KK, Yusuf C: Role of antiarrhythmic prophylaxis in acute myocardial infarction. JAMA 1993; 13: 1589-1595.
45. 14C. Ceremuzynski Y, Kleczar E, Krzeminska-Pekula M et al: Effect of amiodarone on mortality after myocardial infarction. J Am Coll Cardiol 1992; 20: 1056-1062.
46. 15C. Doval HC, Null DR: Randomized trial of low dose of amiodarone in severe congestive heart failure. Lancet 1194; 344: 493-498.
47. 16C. Singh BN: Choice and chance in drug therapy of cardiac arrhythmias: techniques versus drug-specific responses in evaluation of efficacy. Am J Cardiol 1993; 72: 114F-124F.
48. 17C. Herre JM, Sauve MJ, Maione P et al: Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13: 442-449.
49. 18C. Naccarella F, Bracchetti D, Mezzetti M, Palmieri M, Accorsi A, Barbato G, Medda M: The use of antiarrhythmic agents in Italy, in some european countries (France, Spain and Germany) and in United States. Preliminary reports of an ongoing "National and International survey of antiarrhythmic agents use" (NISA) in M. Santini editore, Progress in Clinical Pacing 1994, Chapter 53, 755-789. Futura Publishing Company Inc Armonk New York 10504, 1995.
50. 19C. Bracchetti D, Naccarella F, Sangiorgio P: Coronary events in the EMIAT study. Substudy project. Cardiac angiografhic data (coronary anatomy and LV status) in a subgroup of the EMIAT population (CAD-EMIAT). Relation to arrhythmic (VT/VF, SD,...) or major coronary events (Ami, Unstable Angina,...). In press 1995.
51. 20C. Abstracts and Final Program of the 14 Annual Scientific Session of the NASPE, North American Society of Pacing and Electrophysiology. San Diego, California USA 1993.
52. 21C. Hine LK, Laird NM et al: Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989; 262: 3037-3040.
53. 22C. MINICOURSE 8: Prevention of cardiac arrest in high risk individuals: data from epidemiologic studies and randomized trials. M.J. Domanski, R.J. Myerburg. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
54. 23C. CLINICAL TUTORIALS 17: Selecting the best antiarrhythmic drug for sudden death: betablockers, sotalol, amiodarone or pure class IIIs. R.J. Sung, P. Dorian, NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
55. 24C. Camm AJ for the EMIAT investigators: European Myocardial Infarction Amiodarone Trial (EMIAT). In Chatterjee K, Lazzara R, Clinical trials update. Session: New therapeutic strategies emerging from clinical trials. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
56. 1D. Aronow WS, Mercando AD: Decrease in mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an antiischemic than an antiarrhythmic effect. Am J Cardiol 1994; 15: 74: 6: 613-615.
57. 2D. Morganroth J: Indications for antiarrhythmic suppression of ventricular arrhythmias: a definition of life-threatening ventricular arrhythmias. Am J Cardiol 1993; 72: 2A-7A.
58. 3D. Kulakowski P, Bashir Y: Effects of antiarrhythmic agents on signal-averaged ECG in relation to the results of ventricular stimulation studies. Eur Heart J 1992; 13 (Suppl) 2211.
59. 4D. Brodsky MA, Chough SP, Allen BJ: Adjuvant metoprolol improves efficacy of class I antiarrhythmic drugs in patients with inducible monomorphic ventricular tachycardia, Am Heart J 1992; 124: 629.
60. 5D. Steinbeck G, Andersen D et al: A comparison of electro-physiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med 1992; 327: 987-992
61. 1E. Mason JW: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 7: 452-458.
62. 2E. Freedman RA, Steinberg JS: Selective prolongation of QRS late potential by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. J Am Coll Cardiol 1991; 17: 1017-1025.
63. 3E. Cha YM, Peters BB: Use dependent effects of lidocaine on the upper limit of vulnerability in open chest dogs. J Am Coll Cardiol 1994; 23: 1688-1692.
64. 4E. Karagonis LA, Anderson JL: Electrophysiologic effects of antiarrhythmic drug therapy in the prediction of successful suppression of induced ventricular tachycardia. Am Heart J 1995; 129: 343-349.
65. 5E. Mitrani RD, Biblo LA, Carlson MD: Multiple monomorphic ventricular tachycardia configurations predict failure of antiarrhythmic drug therapy guided by electrophysiologic study. J Am Coll Cardiol 1993; 22: 4: 1117-1122.
66. 6E. Bonavita GJ, Pires LA, Wagshal AB: Usefulness of oral quinidine - mexiletine combination therapy for sustained ventricular tachyarrhythmias as assesses by programmed electrical stimulation when quinidine monotherapy has failed. Am Heart J 1994; 17: 847-851.
67. 7E. Campbell TJ: Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST. Cardiovas Drugs Ther 1992; 6: 519-528.
68. 8E. Singh S, Klein R: Long term effects of mexiletine on left ventricular function and relation to suppression of ventricular arrhythmia. Am J Cardiol 1990; 66: 1222-1227.
69. 9E. Sato S, Tsuji MH: Mexiletine has no effect on defibrillation energy requirements in dogs. PACE 1994; 17Ptl: 2279-2284.
70. 10E. Morita H, Hirabayashi K: Chronic effect of oral mexiletine administration on left ventricular contractility in patients with congestive heart failure: a study based on mitral regurgitant flow velocity measured by continuous wave doppler echocardiography. J Clin Pharmacol 1995; 35: 478-483.
71. 11E. Autori Vari: Combined use of antiarrhythmic drugs. Cardiovascular Drugs and Therapy 5: supplement 1991; 4: 1-125.
72. 1F. Rae AP, Kay HP, Horowitz LN: Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing.
73. 2F. Naccerella F, Btacchetti D, Guaragna RF, Palmieri M, Barbato G: Proarrhythmia related to the pharmacologic treatment of atrial fibrillation. European Journal of Cardiac Pacing and Electrophysiology 1994; 2 (Suppl 4): 184.
74. 3F. Kerin NZ, Somberg J: Proarrhythmia: definition, risk factors, causes treatment and controversies. Am Heart J 1994; 128: 575-585.
75. 4F. Roden DM: Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994; 331: 12: 785-791.
76. 5F. Morganroth J, Anderson JL: Classification by type of ventricular arrhythmias predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986; 8: 607-615.
77. 6F. Naccarella F: Proarrhythmia related to the pharmacological treatment of atrial fibrillation or flutter. Part I-Definition, classification, types and mechanisms. Cardiostimolazione 1995; 13: 229-239.
78. 7F. Naccarella F: Proarrhythmia related to the pharmacological treatment of atrial fibrillation and flutter. Part II-Prevalence with different antiarrhythmic agents in controlled clinical trials. Cardiostimolazione 1995; 13: 241-255.
79. 8F. Minicourse 9: Loong QT and torsades de pointes. Electrophysiologic and molecular basis. N El Sherif, D.M. Roden, NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
80. 9F. Clinical Tutorial 1: Antiarrhythmic and proarrhythmic correlates of prolonged cardiac repolarization, S.A. Hohnloser, A.M. Gillis. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
81. 10F. Comptom SJ: Gene-derived therapy in inherited long QT syndrome: correction of abnormal repolarization by potassium. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
82. 11F. Clinical Tutorial 44: Ventricular hypertrophy and arrhythmogenesis-Electrophysiologic and molecular basis. (A) R. J Myerburg, R. Aronson. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
83. 12F. Core Curriculum 5: Basic cardiac electrophysiology: ion channels for arrhythmias. N. El Sherif, R. Lazzara, NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
84. 13F. Core Curriculum 8: Basic electrophysiology: new concepts in arrhythmogenesis. J. Jalife, M. R. Rosen. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
85. 14F. Core Curriculum 10: Polymorphic ventricular tachycardia. Mechanisms and management. B. Belhassen, J. Brugada. NASPE 17 Annual Sceintific Sessions. May 15-18, 1996. Seattle USA.
86. 15F. Coumel P: Coumel PVT with normal QT interval. In Polymorphic ventricular tachycardia, Mechanisms and management. B. Belhassen, J. Brugada. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
87. 16F. Featured Symposium Long QT syndrome: P.J. Schwartz, G.M. Vincent. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
88. 17F. Camm AJ: Drug induced Torsades de Pointe. In Featured Symposium Long QT syndrome. P.J. Schwartz, G.M. Vincent. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
89. 18F. Featured Symposium VI: Sudden and non sudden death in congestive heart failure. P.C. Deedwania, B.N. Singh. Featured Symposium Long QT syndrome. P.J. Schwartz, G.M. Vincent. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
90. 1G. Adhar GC, Larson LW: Sustained ventricular arrhythmias: differences between survivors of cardiac arrest and patients with recurrent sustained ventricular tachycardia. JACC 1988; 12: 159-165.
91. 2G. Francis GS: Should asymptomatic ventricular arrhythmias in patients with congestive heart failure be treated with antiarrhythmic drugs. JACC 1988; 12: 1: 274-283.
92. 3G. Moser DK, Stevenson WG: Timing of sudden death in patients with heart failure. JACC 1994; 24: 963-967.
93. 4G. Deedwania PC: Triggers and timing of coronary events and sudden death. JACC 1994; 24: 4: 968-971.
94. 5G. Autori vari ANMCO Area Scompenso: Aritmie ipercinetiche ventricolari complesse ed asintomatiche: un difficile problema decisionale quotidiano. G Ital Cardiol 1994; 24: 1333-1339.
95. 6G. Tommaselli GF, Beuckelmann DJ, Calkins HJ et al: Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 1994; 90: 2534-2539.
96. 7G. Kannel WB, Phlen JF, Cupples LA et al: Cardiac failure and sudden death in the Framingham study. Am Heart J 1988; 115: 869-875.
97. 8G. Deedwania PC: Ventricular arrhythmias in heart failure: to treat or not to treat. Cardiol Clin 1994; 12: 115-132.
98. 9G. Gettes LS: Electrolyte abnormalities underlying lethal ventricular arrhythmias. Circulation 1992; 85: I-70-I-76.
99. 10G. Fanapazir L, Chang AC, Epstein SE: Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, holter, hemodynamic and electrophysiological findings. Circulation 1992; 86 (3): 730-740.
100. 11G. Spirito P, Rapezzi C: Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and non sustained ventricular tcahycardia on antiarrhythmic agents. Circulation 1994; 90: 2743-2747.
101. 12G. Naccarella F, Palmieri M, Accorsi A et al: Benign long-term prgnosis of frequent and complex ventricular arrhythmias in apparently healthy subjects, but evidence over time of silent underlying cardiac diseases. J of Ambulatory Monitoring 1994; 7 (2): 171.
102. 13G. Naccarella F, Palmieri M, Accorsi A, Batbato G, Pavesi PC, Bracchetti D: Prevalence and ambulatory monitoring features of non-sustained ventricular tachycardia in a non-selected patient population. Part One. J of Ambulatory Monitoring 1994; 7 (2): 193.
103. 14G. Anderson G: Effect of prophylactic antiarrhythmic therapy on time to implantable cardioverter defibrillator discharge in patients with ventricular tachyarrhythmias. Am J Cardiol 1994; 73: 683-687.
104. 15G. Trappe HJ: Risk and benefit of additional aortocoronary by pass grafting in patients undergoing cardioverter defibrillator implantation. Am Heart J 1994; 127: 75-82.
105. 16G. Treatment of Malignant ventricular arrhythmias. How to... in Piccolo E. Atti del Cardiac Arrhythmias. Fourth International Workshop, Venezia 6/8 ottobre 1995.
106. 17G. Naccarelli GV, Dougherty AH, Wolbrette D: Antiarrhythmic drug- implantable cardioverter/defibrillator interactions. In: M. Santini (ed): Progress in Clinical Pacing 1994. Futura Publishing Company Inc, Armonk, New York, 1995; 135-164.
107. 18G. Greene HL: Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study. Am Heart J 1994; 127: 4 pt 2: 1171-1178.
108. 19G. Naccarella F, Cavasinni L: La tachicardia ventricolare non sostentua. Aspetti diagnostici prognostici e terapeutici. G Ital Cardiol 1995; 25: 95-115.
109. 20G. Cannon DS, Moss AJ: The major prospective randomized trials in ICD therapy in Program of the 16th Annual Scientific Session of the NASPE, North American Society of Pacing and Electrophysiology. Boston, Massachusetts, USA 3-6 Maggio, 1995.
110. 21G. Abstracts and final Program of the 14th Annual
111. 30G. Scientific Session of the NASPE, North American Society of Pacing and Electrophysiology. San Diego, California, USA 1993.
112. 22G. Moosvi AR, Golstein S, Vanderbrug Medentorp S et al: Effect of empiric antiarrhythmic therapy in resuscitated out of hospital cardiac arrest victims with coronary artery disease. Am J Cardiol 1990; 65: 1192-1197.
113. 23G. Hine LK, Laird NM et al: Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989; 262: 3037-3040.
114. 24G. Boden WE: Meta-analysis in clinical trials reporting: has a tool become a weapon? Am J Cardiol 1992; 69: 681-686.
115. 25G. Hallstrom AP, Cobb LA Huiy UB et al: An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 1991; 68: 1025-1031.
116. 26G. Fogoros RN, Elson JJ et al: Long-term outcome of survivors of cardiac arrest whose therapy is guided by electrophysiologic testing. J Am Coll Cardiol 1992; 19: 780-788.
117. 27G. Stanton MS: Risk stratification and sudden death prevention trials in congestive heart failure. In Minicourse 8, Prevention of cardiac arrest in high risk individuals: data from epidemiologic studies and randomized trials. MJ Domanski, RJ Myerburg. NASPE 17 Annual Scientific Sessions. May 15-18, 1996, Seattle USA.
118. 28G. Featured Symposium VI: Sudden and non sudden death in congestive heart failure. PC Deedwania, BN Sigh, In Featured Symposium Long QT syndrome. PJ Schwartz, GM Vincent. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Sattle USA.
119. 1H. Tchou PJ, Kadri N, Anderson J et al: Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 1988; 109: 529-534.
120. 2H. Fogoros RN, Elson JJ, Bonnet CA et al: Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990; 16: 381-386.
121. 3H. Cannon DS, Moss AJ: The major prospective randomized trials in ICD therapy in Program of the 16th annual scientific session of the NASPE. North American Society of Pacing and Electrophysiology. Boston, Massachusetts, USA 3-6 Maggio 1995.
122. 4H. Kim SG: Impact of implantable cardioverter-defibrillator therapy on patient survival. Cardiol Rev 1994; 2: 113-121.
123. 5H. Naccarelli GV, Veltri EP: Implantable Cardioverter-Defibrillators. Series in Interventional Cardiology. Blackwell Scientific Publications Oxford 1993.
124. 6H. Fazio G, Veltri EP: Long term follow up of patients with non ischemic dilated cardiomyopathy and ventricular tachyarrhythmias treated with implantable cardioverter defibrillators. PACE 1991; 14 (Pt 2): 1905-1920.
125. 7H. Choue CW, Furman S: Comparison of defibrillator therapy and other therapeutic modalities for sustained ventricular tachycardia or fibrillation associated with coronary artery disease. Am J Cardiol 1994; 73: 1075-1079.
126. 8H. Brooks R, Ruskin J: Three years outcome of non thoracotomy approach to cardioverter defibrillator implantation in 189 consecutive patients. Am J Cardiol 1994; 74: 1011-1015.
127. 9H. Anderson G: Effect of prophylactic antiarrhythmic therapy on time to implantable cardioverter defibrillator discharge in patients with ventricular tachyarrhythmias. Am J Cardiol 1994; 73: 683-687.
128. 10H. Trappe HJ: Risk and benefit of additional aortocoronary by pass grafting in patients undergoing cardioverter defibrillator implantation. Am Heart J 1994; 127: 75-82.
129. 11H. Fan W: Survival and incidence of appropriate shocks in recipients who have no detectable structural heart disease The CEDARS study. Am J Cardiol 1994; 74: 687-690.
130. 12H. Saksena A and the PCD investigator group: Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter defibrillator implanted with and without thoracotomy: an international multicenter study. J Am Coll Cardiol 1994; 23: 1521-1530.
131. 13H. Wood MA, Ellenbogen KA: Lessons learned from data logging in a multicenter clinical trial using a late generation implantable cardioverter-defibrillator, the Guardian ATP 4210 Multicenter Investigators Group. J Am Coll Cardiol 1994; 24: 1622-1699.
132. 14H. Kelly PA, Mann DE, Damle RS, Reiter MJ: Oversensing during ventricular pacing in patients with a third generation implantable cardioverter defibrillator. J Am Coll Cardiol 1994; 23: 1531-1534.
133. 15H. Mills PS, Minhnich ME: Manged Care and Cardiac pacing and electrophysiology. PACE 1993; 16: 1746-1753.
134. 16H. Benditt DG, Lurie K, Adler S and Saksena S: The changing health care environment: can innovation in the treatment of cardiovascular disease be preserved. PACE 1194; 17 (pt I), 370-378.
135. 17H. ACC/AHA Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. Journal of Cardiovascular Electrophysiology 1995; 6 (8): 654.
136. 18H. Treatment of Malignant ventricular arrhythmias. How to... In: Piccolo E: Atti del Cardiac Arrhythmias. Fourth International Workshop, Venezia 6/8 ottobre 1995.
137. 19H. Commissione Congiunta ANMCO, SIC, AIC, GIA: Standard e VRQ in elettrofisiologia ed elettrostimolazione. Napoli, 4 aprile 1996. (In press).
138. 20H. Bigger JT: The CABG Patch Trial in M. Santini editore, Progress in Clinical Pacing 1994, Chapter 56, 809-827. Futura Publishing Company Inc, Armonk, New York 10504, 1995.
139. 21H. Naccarelli GV, Dougherty AH, Wolbrette D: Antiarrhythmic drug- implantable cardioverter/defibrillator interactions. In: M Santini (ed): Progress in Clinical Pacing 1994. Armonk, New York Futura Publishing Company Inc 1995; 135-164.
140. 22H. Kleman JM, Castle LW: Non thoracotomy-versus thoracotomy implantable defibrillators. Intention to treat comparison of clinical aoutcomes (Non Thoracotomy Study). Circulation 1994, 90: 2833-2842.
141. 23H. Jordaens L, Vertongen P, Provenier F: A new transvenous internal cardioverter-defibrillator. implantation technique, complications and short term follow up. Am Heart J 1995; 129: 251-258.
142. 24H. Zipes DP: Results of the international study of the implantable pacemaker cardioverter defibrillator. A comparison of epicardial and endocardial lead system (Epi-Endocardial Lead System Study). Circulation 1995; 92: 59-65.
143. 25H. Trappe HJ, Pfitzner P, Lichten PR: Cardioverter-defibrillator implantation in the catheterization laboratory: initial experiences in 48 patients. Am Heart J 1995; 129: 259-264.
144. 26H. Davidson T, VanRiper S: Implantable cardioverter defibrillators: a guide for clinicians. Heart Lung 1994; 23: 205-215.
145. 27H. Reiter MJ, Fain ES: Predictors of device activation for ventricular arrhyrthmias and survival in patients with implantable pacemakers/defibrillators (CADENCE Investigators). PACE 1994; 17 (9): 1487-1498.
146. 28H. PCD Investigator Group: Clinical outcome of patients with malignant ventricular tachyarrhythmias and multiprogrammable implantable cardioverter-defibrillator implant with or without thoracotomy: an international multicenter study (Pcd Investigator Group). J Am Coll Cardiol 1994; 23: 1521-1530.
147. 29H. Siebels J, Kuck HK: Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (The Cardiac Arrest Study Hamburg). Am Heart J 1994; 127: 1139-1144.
148. 30H. Greene HL: Antiarrhythmic drugs versus implantable defibrillators: the needd for a randomized controlled study. Am Heart J 1994; 127: 4 pt 2: 1171-1178.
149. 31H. Cannon DS, Moss AJ: The major prospective randomized trials in ICD therapy in Program of the 16th annual scientific session of the NASPE, North American Society of Pacing and Electrophysiology. Boston, Massachusetts, USA 3-6 Maggio, 1995.
150. 32H. Naccarella F: L'Uso della terapia antiaritmica alla luce dei grandi trial clinici controllati. Informazioni utili anche da trial non controllati? In: Adomato E (Ed): Atti del Congresso Meridionale di Cardiologia. Reggio Calabria 3-4 Novembre 1995.
151. 33H. Minicourse 8: Prevention of cardiac arrest in high risk individuals: data from epidemiologic studies and randomized trials. MJ Domanski, RJ Myerburg. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
152. 34H. Buxton AE, MUSTT Trial: Rationale and status. In Minicourse 8, Prevention of cardiac arrest in high risk individuals: data from epidemiologic studies and randomized trials. MJ Domanski, RJ Myerburg. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
153. 35H. Cannon DS, Moss AJ: The major prospective randomized trials in ICD therapy in Program of the 16th annual scientific session of the NASPE, North American Society of Pacing and Electrophysiology. Boston, Massachusetts, USA 3-6 Maggio, 1995.
154. 36H. Lazzara R: Clinical trials update. Session: New therapeutic strategies emerging from clinical trials. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.
155. 37H. Moss AJ for the MADIT investigators: Multicenter Automatic Defibrillator Implantation Trial (MADIT). In Chatterjee K, Lazzara R, Clinical trials update. Session: New therapeutic strategies emerging from clinical trials. NASPE 17 Annual Scientific Sessions. May 15-18, 1996. Seattle USA.